Genmab — Juni 2019
-
"Currently, JNJ-372 is trying to use combination therapy with a variety of medications, including Lazertinib.
In particular, Lazertinib has been evaluated as having a strong effect on patients with brain cancer as it was able to cross the blood-brain barrier that JNJ-372 had failed to cross. " http://www.koreabiomed.com/news/articleView.html?idxno=5861
-
New Approaches Target Overcoming Resistance to TKIs in EGFR+ NSCLC https://www.targetedonc.com/news/new-approaches-target-overcoming-resistance-to-tkis-in-egfr-nsclc
-
well, US stiger fint, det hjalp heller ikke
-
Ikke helt ny, men jeg har ikke set den før: Clinical Cancer Research (april 2019):Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia (CLL).Citat: our data demonstrate the anti-tumor mechanisms of daratumumab in CLL; furthermore, we show how co-targeting BTK and CD38 lead to a robust anti-CLL effect, which has clinical implications.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind